China's Gracell Biotechnologies Lists on Nasdaq

The video discusses advancements in CAR T therapy, highlighting its potential to achieve remission in hematology cancers. A novel Fast CAR technology aims to reduce manufacturing time and costs, improving patient access. The company chose NASDAQ for its global reach despite US-China tensions. Affordability remains a challenge, with efforts to lower costs for broader market access. Industry consolidation is expected, and licensing opportunities are explored to expand globally.

What are the challenges related to drug affordability in the context of CAR T therapy?

How does the company plan to address the issue of drug affordability globally?

What is the company's stance on the potential for licensing agreements with US companies?